{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tusamitamab ravtansine","pembrolizumab"],["tusamitamab ravtansine","pembrolizumab","platinum-based chemotherapy"],["tusamitamab ravtansine","pembrolizumab","platinum-based chemotherapy","pemetrexed"]],"indication":"CEACAM5-positive advanced/metastatic non-squamous non-small-cell lung cancer","name":"CARMEN-LC05","nct_id":"NCT04524689","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=carmen-lc05-nct04524689. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CARMEN-LC05","arms":[{"description":"Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.","label":"Tusamitamab ravtasine 150 mg/m^2 + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.","label":"Tusamitamab ravtasine 170 mg/m^2 + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.","label":"Tusamitamab ravtansine 150 mg/m^2 + Pembrolizumab + carboplatin or cisplatin","type":"EXPERIMENTAL"},{"description":"Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.","label":"Tusamitamab ravtansine 170 mg/m^2 + Pembrolizumab + carboplatin or cisplatin","type":"EXPERIMENTAL"},{"description":"Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.","label":"Tusamitamab ravtansine 150 mg/m^2 + Pembrolizumab + carboplatin or cisplatin + pemetrexed","type":"EXPERIMENTAL"},{"description":"Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.","label":"Tusamitamab ravtansine 170 mg/m^2 + Pembrolizumab + carboplatin or cisplatin + pemetrexed","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-12-24","type":"ACTUAL"},"conditions":["Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)"],"enrollment":{"count":57,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"SAR408701 (Tusamitamab ravtansine)","otherNames":["Tusamitamab ravtansine"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-29","lead_sponsor":"Sanofi","official_title":"Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-03-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs)","timeFrame":"Cycle 1 Day 1 up to Cycle 1 Day 21 (cycle duration=3 weeks)"},{"measure":"Doublet Cohort: Objective Response Rate (ORR)","timeFrame":"Tumor assessments performed at baseline, then every 6 weeks for first 24 weeks, and every 9 weeks thereafter, approximately 158.4 weeks"},{"measure":"Quadruplet Cohort: Objective Response Rate","timeFrame":"Tumor assessments performed at baseline, then every 6 weeks for first 24 weeks, and every 9 weeks thereafter, approximately 139.9 weeks"}],"references":[],"start_date":{"date":"2020-10-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","url":"https://clinicaltrials.gov/study/NCT04524689"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/carmen-lc05-nct04524689"}